| Literature DB >> 36046457 |
Malathi Kullappan1, Balakrishnan Anna Benedict2, Anusha Rajajagadeesan3, Padmasini Baskaran4, Nanthini Devi Periadurai5, Jenifer Mallavarpu Ambrose1, Sri Harshini Gandhamaneni6, Aruna Kumari Nakkella7, Alok Agarwal8, Vishnu Priya Veeraraghavan9, Krishna Mohan Surapaneni10.
Abstract
Zika virus is a member of the Flaviviridae family and genus Flavivirus, which has a phylogenetic relationship with spondweni virus. It spreads to humans through a mosquito bite. To identify potential inhibitors for the Zika virus with biosafety, we selected natural antiviral compounds isolated from plant sources and screened against NS3 helicase of the Zika virus. The enzymatic activity of the NS3 helicase is associated with the C-terminal region and is concerned with RNA synthesis and genome replication. It serves as a crucial target for the Zika virus. We carried out molecular docking for the target NS3 helicase against the selected 25 phytochemicals using AutoDock Vina software. Among the 25 plant compounds, we identified NS3 helicase-ellagic acid (-9.9 kcal/mol), NS3 helicase-hypericin (-9.8 kcal/mol), and NS3 helicase-pentagalloylglucose (-9.5 kcal/mol) as the best binding affinity compounds based on their binding energies. To understand the stability of these complexes, molecular dynamic simulations were executed and the trajectory analysis exposed that the NS3 helicase-ellagic acid complex possesses greater stability than the other two complexes such as NS3 helicase-hypericin and NS3 helicase-pentagalloylglucose. The ADMET property prediction of these compounds resulted in nontoxicity and noncarcinogenicity.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36046457 PMCID: PMC9420600 DOI: 10.1155/2022/2044577
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
Figure 1The ZIKV genome comprises structural and nonstructural genes. The location of the nonstructural protein NS3 helicase (PDB: 5JRZ) was highlighted.
Figure 2The stepwise workflow of the complete study.
Figure 3Active sites of the ZIKV NS3 helicase (PDB: 5JRZ). ATP binding site is highlighted in pink.
Molinspiration predicted drug-likeness properties of the phytocompounds.
| S. no. | Phytocompounds | mlogP (<5) | MW (<500) | HBA count (<10) | HBD count (<5) | RB count (<10) | No. of violations |
|---|---|---|---|---|---|---|---|
| 1 | Apigenin | 2.46 | 270.24 | 5 | 3 | 1 | 0 |
| 2 | Baicalein | 2.68 | 270.24 | 5 | 3 | 1 | 0 |
| 3 | Berberine | 0.20 | 336.37 | 5 | 0 | 2 | 0 |
| 4 | Betulin | 7.16 | 442.73 | 2 | 2 | 2 | 1 |
| 5 | Chebulagic acid | 0.07 | 954.66 | 27 | 13 | 5 | 3 |
| 6 | Curcumin | 2.30 | 368.38 | 6 | 2 | 8 | 0 |
| 7 | Ellagic acid | 0.94 | 302.19 | 8 | 4 | 0 | 0 |
| 8 | Epigallocatechin gallate | 2.25 | 458.38 | 11 | 8 | 4 | 2 |
| 9 | Fisetin | 1.97 | 286.24 | 6 | 4 | 1 | 0 |
| 10 | Geraniin | -0.78 | 952.65 | 27 | 14 | 3 | 3 |
| 11 | Glycyrrhizic acid | 1.97 | 822.94 | 16 | 8 | 7 | 3 |
| 12 | Hypericin | 5.77 | 504.45 | 8 | 6 | 3 | 0 |
| 13 | Hyperoside | -0.36 | 464.38 | 12 | 8 | 4 | 2 |
| 14 | Kaempferol | 2.17 | 286.24 | 6 | 4 | 1 | 0 |
| 15 | Lupeol | 8.29 | 426.73 | 1 | 1 | 1 | 1 |
| 16 | Mimusopic acid | 4.26 | 486.69 | 5 | 4 | 2 | 0 |
| 17 | Mulberroside C | 1.96 | 458.46 | 9 | 5 | 3 | 0 |
| 18 | Myricetin | 1.39 | 318.24 | 8 | 6 | 1 | 1 |
| 19 | Neoandrographolide | 1.17 | 480.60 | 8 | 4 | 7 | 0 |
| 20 | Pentagalloylglucose | 2.76 | 940.68 | 26 | 15 | 16 | 3 |
| 21 | Piperine | 3.33 | 285.34 | 4 | 0 | 3 | 0 |
| 22 | Quercetin | 1.68 | 302.24 | 7 | 5 | 1 | 0 |
| 23 | Rosmarinic acid | 1.63 | 360.32 | 8 | 5 | 7 | 0 |
| 24 | Rutin | -1.06 | 610.52 | 16 | 10 | 6 | 3 |
| 25 | Torvoside | 2.67 | 740.93 | 13 | 7 | 4 | 3 |
MW: molecular weight; RB: rotatable bond.
AutoDock Vina docking results for antiviral phytochemicals against ZIKV NS3 helicase (PDB: 5JRZ).
| S. no. | Phytochemicals | Binding affinity (kcal/mol) |
|---|---|---|
| 1. | Ellagic acid | -9.9 |
| 2. | Hypericin | -9.8 |
| 3. | Pentagalloylglucose | -9.5 |
| 4. | Epigallocatechin gallate | -9.2 |
| 5. | Rutin | -9.1 |
| 6. | Glycyrrhizic acid | -9.1 |
| 7. | Mulberroside | -8.9 |
| 8. | Myricetin | -8.8 |
| 9. | Quercetin | -8.5 |
| 10. | Baicalein | -8.5 |
| 11. | Fisetin | -8.5 |
| 12. | Torvoside | -8.3 |
| 13. | Hyperoside | -8.1 |
| 14. | Kaempferol | -8.0 |
| 15. | Lupeol | -8.0 |
| 16. | Neoandrographolide | -8.0 |
| 17. | Rosmarinic acid | -8.0 |
| 18. | Apigenin | -7.9 |
| 19. | Chebulagic acid | -7.8 |
| 20. | Mimusopic acid | -7.7 |
| 21. | Berberine | -7.7 |
| 22. | Betulin | -7.6 |
| 23. | Curcumin | -7.5 |
| 24. | Geraniin | -7.4 |
| 25. | Piperine | -7.1 |
Specific interaction type of phytochemicals with NS3 helicase of ZIKV (PDB: 5JRZ).
| S. no. | Compounds | Interacting amino acids of NS3 helicase and distances | Hydrophobic contacts |
|---|---|---|---|
| 1 | Ellagic acid | Arg459 (2.1), Gln455 (2.4), Glu231 (1.8 & 1.9), Arg202 (2.1), Thr201 (2.5), Gly199 (2.8), Ala198 (2.8), Leu194 (2.0), and His195 (2.1) | Arg776, Thr790, Leu858, Cys775, Leu777, Lys745, Asp855, Thr854, Met766, Leu844, Val726, Met793, Cys797, Ala743, Leu792, Leu718, Met1002, and Gly796 |
|
| |||
| 2 | Hypericin | Glu286 (2.7 & 3.4), Gly415 (2.6), Glu231, Thr201 (2.4), and Lys200 (2.2 & 2.3) | Gly415, Glu231, Ala416, Arg462, Arg202, Gly197, Asn417, and Gly199 |
|
| |||
| 3 | Pentagalloylglucose | Asp410 (1.9 & 2.6), Met414 (2.0), Asp540 (1.9, 2.6 & 2.1), and Arg226 (2.0 & 2.1) | Asp291, Val227, Glu413, Arg388, Thr225, Ile411, Phe391, Cys262, Ala264, and Phe289 |
Figure 4Binding mode of ZIKV NS3 helicase (PDB: 5JRZ) with ellagic acid obtained through AutoDock Vina docking. A close view represents the amino acid interaction between the NS3 helicase (PDB: 5JRZ) and ellagic acid.
Figure 5Binding mode of ZIKV NS3 helicase (PDB: 5JRZ) with hypericin obtained through AutoDock Vina docking. A close view represents the amino acid interaction between the NS3 helicase (PDB: 5JRZ) and hypericin.
Figure 6Binding mode of ZIKV NS3 helicase (PDB: 5JRZ) with pentagalloylglucose obtained through AutoDock Vina docking. A close view represents the amino acid interaction between the NS3 helicase (PDB: 5JRZ) and pentagalloylglucose.
Figure 7RMSD plot obtained through GROMACS trajectory analysis. (a) RMSD plot of protein backbone for complexes such as NS3 helicase (PDB: 5JRZ)-ellagic acid (blue), NS3 helicase (PDB: 5JRZ)-hypericin (red), NS3 helicase (PDB: 5JRZ)-pentagalloylglucose (black), and unbound NS3 helicase (PDB: 5JRZ) (green). (b) RMSD plot for ligand atoms ellagic acid (indigo), hypericin (cyan), and pentagalloylglucose (orange).
Figure 8RMSF plot obtained through GROMACS trajectory analysis. (a) RMSF per residue plot for protein-ligand complexes, NS3 helicase (PDB: 5JRZ)-ellagic acid (blue), NS3 helicase (PDB: 5JRZ)-hypericin (red), NS3 helicase (PDB: 5JRZ)-pentagalloylglucose (black), and unbound NS3 helicase (PDB: 5JRZ) (green). (b) RMSF plot for ligand atoms ellagic acid (indigo), hypericin (cyan), and pentagalloylglucose (orange).
Figure 9Rg plot for Cα atoms obtained through GROMACS trajectory analysis. Rg plot for NS3 helicase (PDB: 5JRZ)-ellagic acid (blue), NS3 helicase (PDB: 5JRZ)-hypericin (red), NS3 helicase (PDB: 5JRZ)-pentagalloylglucose (black), and unbound NS3 helicase (PDB: 5JRZ) (green).
Figure 10H-bond interactions were obtained through GROMACS trajectory analysis. Number of H-bonds formed between the NS3 helicase (PDB: 5JRZ)-ellagic acid (blue), NS3 helicase (PDB: 5JRZ)-hypericin (red), and NS3 helicase (PDB: 5JRZ)-pentagalloylglucose (black).
Binding free energy calculation for ellagic acid, hypericin, and pentagalloylglucose through the MMPBSA method.
| S. no. | Protein-ligand complex | Δ | Δ | Δ | Δ | SASA (kJ/mol) |
|---|---|---|---|---|---|---|
| 1 | Ellagic acid | −346.4 ± 7.1 | −169.6 ± 7.2 | −213.4 ± 9.6 | 69.2 ± 5.7 | −32.6 ± 1.3 |
| 2 | Hypericin | −343.7 ± 6.4 | −167.5 ± 7.1 | −211.3 ± 8.7 | 64.6 ± 4.3 | −29.5 ± 2.3 |
| 3 | Pentagalloylglucose | −338.5 ± 8.6 | −164.9 ± 8.9 | −209.7 ± 7.9 | 67.5 ± 8.1 | −31.4 ± 7.6 |
ADMET calculations.
| Models | Ellagic acid | Hypericin | Pentagalloylglucose |
|---|---|---|---|
| BBB | BBBpositive | BBBnegative | BBBpositive |
| HIA | HIApositive | HIApositive | HIAnegative |
| Caco-2 permeability | Caco2negative | Caco2positive | Caco2negative |
| P-gp substrate | Substrate | Substrate | Substrate |
| P-gp inhibitor | Noninhibitor | Noninhibitor | Noninhibitor |
| Renal organic cation transporters (OCTs) | Noninhibitor | Noninhibitor | Noninhibitor |
| CYP450 2C9 substrate | Nonsubstrate | Nonsubstrate | Nonsubstrate |
| 2D6 substrate | Nonsubstrate | Nonsubstrate | Nonsubstrate |
| 3A4 substrate | Nonsubstrate | Nonsubstrate | Substrate |
| 1A2 inhibitor | Noninhibitor | Inhibitor | Noninhibitor |
| 2C9 inhibitor | Noninhibitor | Inhibitor | Noninhibitor |
| 2D6 inhibitor | Noninhibitor | Noninhibitor | Noninhibitor |
| 2C19 inhibitor | Noninhibitor | Inhibitor | Noninhibitor |
| 3A4 inhibitor | Noninhibitor | Inhibitor | Noninhibitor |
| AMES test | Non-AMES toxic | Non-AMES toxic | Non-AMES toxic |
| Carcinogens | Noncarcinogens | Noncarcinogens | Noncarcinogens |